Newly-Named KaloBios Pharma (KBIO) CEO Shkreli Briefly Comments on Twitter About Appointment

Incoming KaloBios Pharma (NASDAQ: KBIO) CEO Martin Shkreli posted the following to Twitter late Thursday night:

Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares $KBIO

— Martin Shkreli (@MartinShkreli) November 20, 2015

So happy to rescue $KBIO from having to discontinue our promising blood cancer drug lenzilumab. Let's hire the downsized employees back too!

— Martin Shkreli (@MartinShkreli) November 20, 2015

You May Also Be Interested In

• McDonald's (MCD) Raises Quarterly Dividend 3.8% to $1.93; 3.1% Yield
• FedEx: targets 30% of jet fuel from alternative sources by 2030 - Reuters
• 3M Co. (MMM) expects higher oil costs to be offset dollar-for-dollar through pricing, with no impact on earnings